Logo
  • About
  • Contact
  • (888) 441-8033

MD HEALTHCARE INC. TO PRESENT AT BIOTECH SHOWCASE™ 2020 IN SAN FRANCISCO

[Seoul/December 31, 2019] – MD Healthcare Inc. today announced that it has scheduled a company presentation at Biotech Showcase™ 2020, to be held January 13–15, during the most important week in healthcare at the Hilton San Francisco Union Square. B&D Specialist Andrea McDowel...

View full release

Salarius During the JP Morgan Week - Attend the Biotech Showcase Presentation or Join the Live Webcast

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by mis-regulated gene expression, referred to as epigenetics, has announced that its chief executive officer, David Arthur, will present at the Biotech Showcase 2020 ...

View full release

NanoValent: Novel Platform To Develop Targeted Cancer Therapeutics

NanoValent continues to progress towards its goal of moving our lead drug candidate to an IND/BLA and the clinic in 2021 and 2022. Although our “almost virtual” infrastructure has us sheltering-in-place as a regular course of business, these are by no means normal times.  Yet,...

View full release

CuRAGE THERAPEUTICS TO PRESENT ITS CR-3 BREAKTHROUGH  DISEASE-MODIFYING THERAPY FOR PERIPHERAL ARTERY DISEASE AT BIOTECH SHOWCASE 2020

Berwyn, PA – DEC. 24, 2019 – CuRAGE Therapeutics announced today that it is scheduled to deliver a company presentation at Biotech Showcase™ 2020, to be held January 13–15, during the most important week in healthcare at the Hilton San Francisco Union Square. Dr. Ihor Terlecky...

View full release

PCLX-001 has robust efficacy in leukemia and lymphoma.

Privately-held Pacylex may have a gem in its pipeline. Pacylex is developing PCLX-001, a first-in-kind, small molecule with a novel mechanism of action believed to play a significant role in the development of certain types of blood cancers and solid tumors. Data from four dif...

View full release

Lachesis Biosciences: Advancing A Low-Risk, High-Reward Alzheimer’s Drug

In the world of pharmaceutical product development, an effective drug to treat Alzheimer's disease (AD) is the Holy Grail. Very little has been successful in this area to date. Neurodegenerative diseases remains a difficult area for new product development and Alzheimer's by f...

View full release

UGI and its Employees Demonstrate the Spirit of Giving during the Holiday Season

UGI employees continued a long-standing tradition of giving back to the community throughout the holiday season. UGI employees have shared their spirit of the season in a variety of activities that support a wide range of community organizations across Pennsylvania in providin...

View full release

UGI encourages residents to follow safe energy practices during the holidays

As families and businesses gather to celebrate the holiday season, UGI encourages all members of the community to remember the following energy-related safety tips: Practice good safety habits when using a natural gas oven and stove.  If you use natural gas for cooking, be sur...

View full release

Proprietary phage and endolysin platform targets Implant Infections, Bacterial Vaginosis and UTI

Proprietary discovery and engineering platform to develop precision phage therapies First phage candidate expected to enter the clinic in 2022 Pipeline of antimicrobial-resistance and microbiome applications Estimated $12 Billion addressable market for multi-drug resistant in...

View full release

December National Poll: Biden and Sanders Pull Away from the Pack as Warren Falls

In the latest Emerson College/WHDH National Poll of the Democratic Primary, former Vice President Joe Biden leads at 32%, followed by Senator Bernie Sanders at 25%. Senator Elizabeth Warren comes in third at 12%, followed by Mayor Pete Buttigieg at 8%, and entrepreneur Andrew ...

View full release
  • « First
  • ‹ Prev
  • …
  • 208
  • 209
  • 210
  • 211
  • 212
  • 213
  • 214
  • 215
  • 216
  • …
  • Next ›
  • Last »
©2025 Reportable, Inc.
Terms and Conditions | Privacy Policy